Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study

Authors

  • Mark C. Scholz,

    Corresponding author
    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    • Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, 4676 Admiralty Way, Suite 101, Marina del Rey, CA 90292.
    Search for more papers by this author
  • Meg K. Groom,

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author
  • Andrew J. Kaddis,

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author
  • Stephen B. Strum,

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author
  • Robert I. Jennrich,

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author
  • Duke K. Bahn,

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author
  • Patricia J. Chang,

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author
  • Lauren K. Becker,

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author
  • Richard Y. Lam

    1. Prostate Oncology Specialists, Prostate Institute of America, University of California at Los Angeles, Ashland Community Hospital, Marina del Rey, California
    Search for more papers by this author

Abstract

BACKGROUND

Active surveillance (AS) is only recommended for Low-Risk prostate cancer (PC) with <34% biopsies positive. Studies describing the long-term outcome of men treated with androgen deprivation (AD) followed by AS are sparse.

MATERIALS AND METHODS

One hundred two men were treated with 12 months of AD in a medical oncology clinic specializing in PC between 1998 and 2007 and were followed for a median of 7.25 years. The biopsy complete response rate after AD and the incidence of disease progression while on subsequent AS was assessed. Baseline age, D'Amico risk category, PSA velocity, percentage core biopsies, and prostate volume were evaluated as potential predictors of disease progression.

RESULTS

D'Amico risk category for the 102 men: Low: n = 22, Intermediate: n = 30, and High: n = 50. Medians: Age 67.3, PSA 7.8, Gleason 3 + 4, >50% core biopsies positive, stage T1c. Seventy men had a clear biopsy and 31 of these had disease progression leading to additional treatment after a median of 52 months. D'Amico risk category of the 57 men with a positive biopsy after AD or disease progression on AS was: Low: n = 4 (18%), Intermediate: n = 16 (53%), and High: n = 37 (74%). No PC deaths occurred. Three men had clinical progression. In stepwise logistic regression analysis only higher D'Amico risk category and lower prostate volume predicted disease progression.

CONCLUSIONS

Despite a high prevalence of ≥50% core biopsies positive at baseline, AD induces durable remissions in most men with Low-Risk and about half with Intermediate-Risk PC. Prostate 73: 83–88, 2013. © 2012 Wiley Periodicals, Inc.

Ancillary